Patent · US Active

Form 2 crystalline polymorph of a salt of N-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-B]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl) thiazol-4-yl]-benzamide useful as cysteine protease inhibitor

US9650388B2 · kind B2 · utility

0Cited by

0References

24Claims

0Family size

Assignee

MEDIVIR AB · SE

Inventors

Urszula Grabowska · Huddinge, SE
Lourdes Salvador ODEN · Huddinge, SE
Victor M. Diaz Perez · Cambridge, GB
Andrew Carr · Cambridge, GB

Key dates

Filing date	Aug 13, 2014
Grant date	May 16, 2017
Priority date	—
Expiry date	Aug 13, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There is provided Form 2 crystalline polymorph consisting of N-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazin-1-yl)thiazol-4-yl]-benzamide monohydrochloride and N-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazin-1-yl)thiazol-4-yl]benzamide hydrate monohydrochloride, its use as a medicament and methods for its preparation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.